According to filings with the U.S. Securities and Exchange Commission, Lynch Regenerative Medicine is raising up to $15,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Samuel Lynch played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lynch Regenerative Medicine
LRM (Aesthetics) is pioneering innovative treatments to revolutionize skin health through improved rejuvenation and regeneration to achieve optimal aesthetic results. PDGF (recombinant Platelet-Derived Growth Factor): LRM Aesthetics has unlocked the power of PDGF, one of the most conserved proteins in the animal kingdom because it is so important in stimulating the healing process. Our PDGF is the only molecule that has been proven in award-winning, human clinical trials to promote healing of both skin and bone. In the last 15 years, over five million patients have been successfully treated with our PDGF in four FDA approved modalities. PDGF is the next generation of growth factors supporting skin rejuvenation. In fact, LRM Aesthetics has developed products with PDGF concentrations that are 100 10,000x the concentration measured in PRP, providing dramatically greater potency and consistency in treatment.

To learn more about Lynch Regenerative Medicine, visit http://www.lynchregen.com/

Contact:
Samuel Lynch, Chief Executive Officer
615-218-1624
https://www.linkedin.com/in/samuel-lynch-71456317/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.